Is afamelanotide the same as Melanotan-1?

Afamelanotide is the pharmaceutical name for a synthetic alpha-MSH analog that is closely related to what is sold as Melanotan-1 in research peptide markets. The FDA-approved product (Scenesse) is a controlled- release 16 mg subcutaneous implant manufactured under strict pharmaceutical standards for EPP patients. Research-grade Melanotan-1 sold for injection use is not FDA-approved, may differ in purity, and is used off-label for tanning purposes.

What do EPP patients report about afamelanotide?

EPP patients who have received the Scenesse implant generally report significant improvement in their ability to tolerate sunlight. Reports include being able to spend hours outdoors without the severe phototoxic pain reactions that characterize EPP. Some patients describe it as life-changing for their quality of life. The main reported side effects include nausea, skin darkening, and injection site reactions.

Can afamelanotide be used for cosmetic tanning?

Afamelanotide (Scenesse) is FDA-approved only for EPP and is not indicated for cosmetic tanning. Community discussions about using Melanotan-1 for tanning refer to off-label, unregulated research peptide use that carries significant risks including potential melanoma concerns, nausea, and unpredictable skin darkening. This use is not supported by the pharmaceutical manufacturer or regulatory agencies.

Afamelanotide: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 30 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•2 community protocols documented
•Evidence level: Anecdotal Reports
•Based on 30 community reports
•1 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Approved vs. Off-Label Use	Afamelanotide is FDA-approved exclusively for erythropoietic protoporphyria (EPP) as a 16 mg subcutaneous implant administered by healthcare providers every 2 months.	Community discussions sometimes conflate afamelanotide with Melanotan-1, its research-grade counterpart. Some users in tanning and peptide communities discuss using Melanotan-1 for cosmetic tanning, though this is not the same as the pharmaceutical-grade implant.	high The FDA-approved Scenesse implant is a controlled-release pharmaceutical product with strict prescribing criteria. Research-grade Melanotan-1 is not equivalent in purity, dosing, or safety profile.
Administration Route	The approved route is a subcutaneous implant providing sustained release over approximately 60 days, administered by a healthcare professional.	Off-label community use (as Melanotan-1) involves daily subcutaneous injections rather than an implant, resulting in different pharmacokinetics with peak-and-trough dosing patterns.	high The implant provides sustained, steady-state drug levels, while injection-based use results in daily peaks and troughs. Safety and efficacy data from implant trials do not directly apply to injection use.

Compare these community approaches with published research findings.

Community Protocols

FDA-Approved EPP Protocol

Popular

Route: Subcutaneous implant
Dose: 16 mg implant
Frequency: Every 2 months (before and during sun exposure periods)
Duration: Seasonal or ongoing

FDA-approved protocol for adults with EPP; administered by healthcare provider

Off-Label Tanning Protocol (Melanotan-1)

Niche

Route: Subcutaneous injection
Dose: 0.5-1 mg daily
Frequency: Daily during loading phase (1-2 weeks), then maintenance
Duration: Variable

Afamelanotide is structurally related to Melanotan-1; some community members discuss off-label tanning use through research peptide channels

Stacking Patterns

Afamelanotide + Sun Exposure Management

Popular

For EPP patients, afamelanotide combined with gradual, controlled sun exposure allows patients to increase pain-free time outdoors

afamelanotide

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 30+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

American Porphyria Foundation|Erythropoietic Protoporphyria (EPP) patient information and community resources(accessed 2026-02-16)
Reddit r/Peptides|Melanotan-1 and afamelanotide discussion threads(accessed 2026-02-16)
United Porphyrias Association|Porphyria patient resources, EPP community, and treatment information(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community reports and patient experiences for afamelanotide (Scenesse). The information below is gathered from EPP patient communities and peptide forums. This is not clinical evidence and should not be used as medical guidance.

Afamelanotide occupies a unique position as an FDA-approved melanocortin agonist with a very specific indication (erythropoietic protoporphyria). Community discussion comes from two distinct populations: EPP patients using the approved implant and peptide enthusiasts interested in melanocortin receptor agonists for tanning.

Important Distinction#

The FDA-approved product (Scenesse) is a subcutaneous implant available only through specialty prescribers for EPP patients. Community discussions about Melanotan-1 for tanning purposes refer to a different use case with unregulated products that are not equivalent to the pharmaceutical implant.

EPP Patient Experiences#

Patients with erythropoietic protoporphyria who have received afamelanotide implants report:

Increased sun tolerance: The most consistently reported benefit, with patients describing significantly extended time outdoors without phototoxic reactions
Quality of life improvement: Many patients describe the ability to participate in outdoor activities as transformative
Skin darkening: Expected pharmacological effect; most patients report noticeable tanning
Nausea: Commonly reported in the days following implant placement, usually transient

Important Caveats#

Afamelanotide is a prescription medication for a specific rare disease
Patient experiences with the approved implant should not be extrapolated to research peptide use
Long-term melanocortin receptor activation and melanogenesis carry theoretical oncological considerations
Access is limited by specialty prescriber requirements and insurance coverage

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.